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Background: The worldwide increasing trend of chronic kidney disease (CKD) is of great concern and the role of
heart disease deserves longitudinal studies. This study investigated the risk of developing CKD among patients with
heart diseases.
Methods: From universal insurance claims data in Taiwan, we retrospectively identified a cohort of 26005 patients
with newly diagnosed heart diseases and 52010 people without such disease from the 2000–2001 claims. We
observed prospectively both cohorts until the end of 2007 to measure CKD incidence rates in both cohorts and
hazard ratios (HR) of CKD.
Results: The incidence of CKD in the cohort with heart disease was 4.1 times greater than that in the comparison
cohort (39.5 vs. 9.65 per 10,000 person-years). However, the HR changed into 2.37 (95% confidence interval (CI) =
2.05 – 2.74) in the multivariate Cox proportional hazard model after controlling for sociodemographic characteristics
and comorbidity. Compared with individuals aged < 40 years, the HRs for CKD ranged from 2.70 to 4.99 in older
age groups. Significant estimated relative risks of CKD observed in our patients were also independently associated
with hypertension (HR = 2.26, 95% CI = 1.94 - 2.63) and diabetes mellitus (HR = 2.44, 95% CI = 2.13 - 2.80), but not
with hyperlipidemia (HR =1.13, 95% CI = 0.99-1.30).
Conclusions: This population study provides evidence that patients with heart disease are at an elevated risk of
developing CKD. Hypertension and diabetes mellitus are also comorbidity associated with increasing the CKD risk
independently.Background
The cardiac and renal diseases are always coexisting and
may significantly increase mortality, other complications,
and the cost of health care [1,2]. Heart diseases and
chronic kidney disease (CKD) are thus often diagnosed
and cared simultaneously in clinical practices. But, the
nature of this association has not been well identified
despite physicians’ efforts to take the clinical history in
detail. The term “cardiorenal syndrome” (CRS)* Correspondence: fssung1008@yahoo.com; cch@mail.cmuh.org.tw
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reproduction in any medium, provided the orrepresents the concept of primary disorder of either the
heart or kidney often results in secondary injury to each
other. CRS has been well defined and classified but has
not yet concluded a consensus process [3,4]. Studies have
reported the interaction between chronic cardiac dysfunc-
tion and CKD, focusing the attention on the direction of
primary CKD in the effect on heart disorders [5-10].
Although reports have provided data on CKD preva-
lence in heart diseases [11,12], several issues remain to
be clarified. First, these study populations have been
based on ethnic Caucasians and African Americans, and
there are scant data on the ethnic Asian populations.
Second, the subject number has been limited, cross-
sectional design; fragmented appreciation of epidemi-
ology, or the follow-up time has been relatively short.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ology of CRS is that patients may be also in transition
between acute and chronic condition at various time
points. For these reasons, we need more evidence;
knowing if this association between primary chronic
heart dysfunction and subsequent development of CKD
is real.
This study, a retrospective cohort study on ethnic
Chinese, provides a unique opportunity to investigate
the incidence of new-onset CKD among patients with
pre-existing heart disease. The study subjects were of
homogenous ethnicity. Longitudinal follow-up data
made causal inference possible. We investigated whether
heart disease has effect on subsequent development of
CKD in this cohort.
Methods
Data source and study population
The Taiwan National Health Insurance (NHI), a univer-
sal health program established in 1995, has covered
more than 96% of all 23 million people and has
contracted with 90% of the hospitals and practitioners
since 1996. We obtained the claims data of the Longitu-
dinal Health Insurance Database established by the
National Health Research Institute, Department of Health,
Taiwan. This data contained the registry of a randomly
selected one million insured people as of 2005. The
claims data covered ambulatory care claims registry (CD),
inpatient claims (DD) and the updated registry for bene-
ficiaries (ID) in 1996–2007. We used the scrambled
identification number to link data sets to safeguard the
confidentiality of the insured population without ethical
violation. This study was thus exempted from the ethical
review.
Study subjects
The study cohort of heart diseases consisted of new
patients with at least 2diagnostic records of the heart
disease in 2000–2001 based on The International classi-
fication of Disease, 9th Revision, Clinical Modification
(ICD-9-CM) codes. They were rheumatic heart disease
(ICD-9-CM 391, 393–398, and A-code 251), hyperten-
sive heart disease (ICD 402), ischemic heart disease
(ICD 410–414, and A270, A279) and others (ICD 420–
429 and A281). The comparison cohort consisted of ran-
domly selected people insured in 2000–2001 without
heart diseases and frequency matched with age. We also
excluded subjects with CKD at baseline (ICD-9-CM
code 585), identified before the date subjects were
selected for inclusion in the study. CKD is defined based
on the glomerular filtration rate and/or abnormal serum
creatinine concentration by the Taiwan Association of
Nephrology which had established a registry system for
CKD. The accuracy of diagnosis is the primaryrequirement for the registry system. Eventually, there
were 26005 heart disease cases and 52010 references in
this study. Patients with the baseline comorbidity includ-
ing hypertension (ICD-9-CM 401–405 and A-code A260
A269), diabetes mellitus (ICD-9-CM 250 and A-code
A181), and hyperlipidemia (ICD-9-CM 272 and A-code
A182) were also identified. The Bureau of National
Health Insurance conducted periodic review of claims
data to ensure the accuracy of claims.
Statistical analysis
Data analysis compared distributions of age, sex, occupa-
tion, residential area, income, and comobidity between
the study cohort (subjects with heart disease) and the
comparison cohort (subjects without heart disease),
which were examined by Chi-square test. We calculated
the incidence density rates of CKD by these variables
and the corresponding study cohort to comparison co-
hort rate ratios of CKD. For incidence density calcula-
tion, we calculated follow-up person-years for study
subjects until CKD diagnosed, or until 31 December
2007 for those uncensored, or the censoring date for the
censored for other reasons, such as death, emigration
and termination of the insured program. The same pa-
tient might have multiple admissions with different CKD
stages. Only the first CKD event was used to estimate
the follow-up person-years. Variables that were categor-
ized included age (< 40, 40–49, 50–59 and ≥ 60 years),
residential area (north, central, south, and east and off
islands) and income [less than New Taiwan Dollar
(NTD) 15,000, 15,000-29,999, and more than 30,000/
per month], urbanization level (population density) of
residential township or district (high, moderate, and
low) and occupation (white collar, blue collar, and
others).We calculated hazard ratios (HRs) and 95% con-
fidence interval (CI) using Cox hazard proportional
model to assess the hazard ratio of CKD for patients
with the heart disease. Two multivariate models were
used by controlling categorical covariates. One model
included sociodemographic variables with significant as-
sociation. The other model included also baseline
comorbidity. A plot of the Kaplan-Meier analysis was
used to show the probability of persons remaining with-
out CKD, and the log-rank test was used to test the dif-
ference between the study cohort and the comparison
cohort. All analyses were performed by SAS statistical
software (version 9.1 for Windows; SAS Institute, Inc.,
Cary, NC, USA). The hazard ratios are presented with
95 percent CIs, and p-values are two sides.
Results
Subjects characteristics
Table 1 compares distributions of sociodemographic
characteristics and baseline comorbidity status between
Table 1 Comparisons in demographic characteristics and baseline comobidities between cohort of patients with heart
disease and cohort without heart disease diagnosed in 2000-2001
Variables Heart Disease
No Yes† Total
N = 52010 N = 26005 N = 78015
n (%) n (%) n (%) p-value
Sex <0.0001
Female 24733 (47.6) 13829 (53.2) 38562 (49.4)
Male 27277 (52.4) 12176 (46.8) 39453 (50.6)
Age, years 1.00
< 40 11352 (21.8) 5676 (21.8) 17028 (21.8)
40-49 10438 (20.1) 5219 (20.1) 15657 (20.1)
50-59 10584 (20.4) 5292 (20.4) 15876 (20.4)
≥ 60 19636 (37.8) 9818 (37.8) 29454 (37.8)
Occupation 0.26
White collar 20386 (39.2) 10050 (38.7) 30436 (39.0)
Blue collar 20785 (40.0) 10434 (40.1) 31219 (40.0)
Others 10839 (20.8) 5521 (21.2) 16360 (21.0)
Urbanization† 0.63
Low 7889 (15.2) 3954 (15.2) 11843 (15.2)
Moderate 10167 (19.6) 5154 (19.8) 15321 (19.6)
High 33954 (65.3) 16896 (65.0) 50850 (65.2)
Region† <0.0001
North 23081 (44.4) 11334 (43.6) 34415 (44.1)
Central 9988 (19.2) 5641 (21.7) 15629 (20.0)
South 14231 (27.4) 6691 (25.7) 20922 (26.8)
East and Island 4710 (9.1) 2338 (9.0) 7048 (9.0)
Monthly income (NTD) <0.0001
<15,000 23332 (44.9) 11748 (45.2) 35080 (45.0)
15,000-29,999 20072 (38.6) 10362 (39.9) 30434 (39.0)
≥30,000 8606 (16.6) 3895 (15.0) 12501 (16.0)
DM{ <0.0001
No 48951 (94.1) 21392 (82.3) 70343 (90.2)
Yes 3059 (5.9) 4613 (17.7) 7672 (9.8)
Hypertension{ <0.0001
No 45261 (87.0) 12628 (48.6) 57889 (74.2)
Yes 6749 (13.0) 13377 (51.4) 20126 (25.8)
Hyperlipidemia{ <0.0001
No 47433 (91.2) 18901 (72.7) 66334 (85.0)
Yes 4577 (8.8) 7104 (27.3) 27.3 (15.0)
Heart Disease: ICD-9 coden (A-code): rheumatic 391, 393–398 (A251), hypertensive 402, ischemic 410–414 (A270, A279), else 420–429 (A281) and times ≥ 2.
Urbanization: low = 1st and 2nd quartile of density of population, moderate = 3rd quartile of density of population, high = 4th quartile of density of population.
Chronic Kidney Disease (CKD): ICD-9 coden: 585 and times ≥ 2 between 2001 and 2007.
Diabetes Mellitus (DM): ICD-9 coden (A-code): 250 (A181) and times ≥ 3.
Hypertension: ICD-9 coden (A-code): 401–405 (A260, A269) and times ≥ 3.
Hyperlipidemia: ICD-9 coden (A-code): 272 (A182) and times ≥ 3.
†1 observation of Heart Disease patients is missing.
{The dates of diagnosis of DM, Hypertension, and Hyperlipidemia were before December 31, 2001.
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there were more females in the study cohort than in the
comparison cohort. Age, occupation and residential
urbanization levels of study subjects were similarTable 2 Incidence densities of chronic kidney disease in hear




All 352 364,887 9.65
Sex
Female 125 173,553 7.20
Male 227 191,335 11.86
Age, years
< 40 6 79,454 0.76
40-49 44 73,240 6.01
50-59 69 74,360 9.28
≥ 60 233 137,834 16.90
Occupation
White collar 101 143,047 7.06
Blue collar 169 145,810 11.59
Others 82 76,030 10.79
Urbanization{
Low 65 55,349 11.74
Moderate 67 71,393 9.38
High 220 238,146 9.24
Region{
North 125 161,939 7.72
Central 63 70,161 8.98
South 121 99,742 12.13
East and Island 43 33,045 13.01
Monthly income (NTD)
<15,000 187 163,776 11.42
15,000-29,999 135 140,693 9.60
≥30,000 30 60,418 4.97
DM}
No 275 343,556 8.00
Yes 77 21,331 36.10
Hypertension}
No 221 317,675 6.96
Yes 131 47,212 27.75
Hyperlipidemia}
No 287 332,801 8.62
Yes 65 32,086 20.26
†per 10,000 person-year.
{1 observation of Heart Disease patients is missing.
}The dates of diagnosis of DM, Hypertension, and Hyperlipidemia were before Decebetween the two cohorts. The distribution of residential
regions and income were somewhat different but signifi-
cant. The study cohort was more prevalent in comorbid-
ity than the comparison cohort including diabetest disease cohort and comparison cohort and rate ratios by
Yes
Case Person-year Rate† Ratio
714 180,736 39.51 4.10
311 96,370 32.27 4.48
403 84,367 47.77 4.03
32 39,618 8.08 10.70
90 36,416 24.71 4.11
132 36,853 35.82 3.86
460 67,850 67.80 4.01
200 69,951 28.59 4.05
320 72,524 44.12 3.81
194 38,261 50.70 4.70
134 27,496 48.73 4.15
154 35,819 42.99 4.58
426 117,413 36.28 3.93
289 78,784 36.68 4.75
157 39,248 40.00 4.45
186 46,492 40.01 3.30
82 16,205 50.60 3.89
386 81,452 47.39 4.15
280 72,062 38.86 4.05
48 27,222 17.63 3.55
404 149,045 27.11 3.39
310 31,691 97.82 2.71
133 87,930 15.13 2.17
581 92,806 62.60 2.26
433 131,402 32.95 3.82
281 49,334 56.96 2.81
mber 31, 2001.
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and hyperlipidemia (27.3% vs. 8.8%).
Risk and crude relative risk of CKD
Table 2 summarizes the CKD incidence densities in the
observed follow-up period for the two cohorts, and
study cohort to comparison cohort rate ratios. There
were 714 cases of CKD identified in a follow-up of
180,736 person-years in the cohort with heart disease,
and 352 cases of CKD in 364,887 person-years in the
comparison cohort. The incidence rate ratio of CKD in
the study cohort was 4.1 times higher than that in the































Model 1: Cox hazard proportional analysis without adjustment.
Model 2: Multivariate Cox hazard proportional analysis including age, sex, occupatio
Model 3: Multivariate Cox hazard proportional analysis including age, sex, occupatio
†One missing in model 2 and model 3.
*p < 0.05, **p < 0.01,***p < 0.001.years). The rate ratios measured by the categorized
sociodemographic status ranged 3.30 to 4.75. The study
cohort less than 40 years of age had a much greater rate
ratio of 10.7. The incidence rate ratios were 2.71 for sub-
jects with diabetes mellitus, 2.26 for those with hyper-
tension and 2.81 for those with hyperlipidemia.
Hazards of CKD
The association of developing CKD was significantly
greater in men than women and the HR increased with
age in the multivariate Cox model (Table 3, model 2 and
model 3). The HR of developing CKD was augmented
with age after adjusted for socioeconomic factors (Table 3,e
Model 2 Model 3
HR (95% CI) HR (95% CI)
1.00 (reference) 1.00 (reference)
4.20 (3.70-4.78)*** 2.37 (2.05-2.74)***
1.00 (reference) 1.00 (reference)
1.50 (1.32-1.69)*** 1.56 (1.38-1.77)***
1.00 (reference) 1.00 (reference)
3.79 (2.64-5.44)*** 2.70 (1.87-3.88)***
5.32 (3.76-7.54)*** 3.17 (2.22-4.52)***
9.23 (6.62-12.87)*** 4.99 (3.55-7.03)***
1.00 (reference) 1.00 (reference)
1.22 (1.01-1.46)* 1.19 (0.99-1.43)
1.01 (0.84-1.20) 0.99 (0.83-1.18)
1.45 (1.11-1.90)** 1.41 (1.08-1.85)*
1.24 (0.94-1.64) 1.28 (0.97-1.69)








n, income, diabetes, hypertension, and hyperlipidemia.
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after additional adjustment for cardiometabolic risks
such as diabetes, hypertension and hyperlipidemia
(Table 3, model 3). In univariate analysis, the HR of
developing CKD for patients with heart disease was
4.10 (CI = 3.61-4.66) (Table 3, model 1). In multivariate
models, the HRs were 4.20 (CI = 3.70-4.78) after
adjusted for baseline sociodemographic factors (Table 3,
model 2) and decreased to 2.37 (95% CI = 2.05 - 2.74)
after adjusted for baseline sociodemographic and cardo-
metabolic factors (Table 3, model 3). The risk of devel-
oping CKD was slightly greater for patients with
comorbidity of diabetes mellitus (HR = 2.44, 95% CI = 2.13
to 2.80) than that of hypertension (HR = 2.26, 95%
CI =1.94 to 2.63) (Table 3, model 3). Patients with
hyperlipidemia had a moderate HR of 1.13 (95% CI
= 0.99 to 1.30) to have CKD with statistically insig-
nificant (p > 0.05).
The plot of Kaplan-Meier analysis displayed that the
CKD-free probability was 2.0 % lower in the study co-
hort than in the comparison cohort (97.3% vs. 99.3%,
log-rank test: p < 0.0001) (Figure 1).
Discussion
New onset of CKD is a frequent phenomenon in Tai-
wanese. The incidence rates of CKD are strongly related
to diabetes mellitus and high blood pressure in the study
subjects, particularly in the heart disease cohort. Among
subjects without heart disease, those with diabetes melli-
tus were 4.5-fold (36.10 vs. 8.00 per 10,000 person-years)
more likely to develop CKD than those without diabetes
mellitus. The risk of developing CKD is particularly highFigure 1 Kaplan-Meier plot for probability of subjects free from
chronic kidney disease in the follow-up period in patients with
heart disease and comparison cohort without heart disease.
(HD = heart disease).for patients with both heart disease and diabetes melli-
tus, with the incidence increased to 97.82 per 10,000
person-years. The risk of developing CKD in patients
with heart disease is followed by those with comorbidity
of hypertension (62.60 per 10,000 person-years) and
hyperlipidemia (56.96 per 10,000 person-years). Cardio-
vascular events play a critically important role in pre-
dicting CKD. The study results showed clearly a much
higher risk of CKD among ethnic Chinese with under-
lying heart diseases and diabetes.
Unlike other studies, our study showed CKD incidence
is not as high as physician’s suspicion in patients with
heart diseases. This is due partly to the study design,
which is related to complete exclusion of CKD patients
at the study baseline in our cohort. This design
decreases the possibility of the effect by a condition of
mixture of cardiac and renal dysfunction at study base-
line. This study has the advantage of a large sample of
participants free of kidney disease at baseline, a long fol-
low up period, and the ability to study the associated
sociodemographic status at its inception. We are also
able to study models composed of baseline comobidity.
The models offer unique and complementary insights
into risk factors for CKD. The baseline risk factor
model is advantage because risk factors clearly precede
outcome.
We have further measured the incidence and HR of
developing CKD for different heart diseases, including
rheumatic heart disease, hypertensive heart disease, ische-
mic heart disease, chronic heart failure and valvular heart
disease. The incidence was the highest for those with
chronic heart failure (68.1 per 10,000 person-years) with
a HR of 3.08 (95% CI = 2.20-4.33), followed by hyperten-
sive heart disease (62.6 per 10,000 person-years), ischemic
heart disease (38.8 per 10,000 person-years), rheumatic
heart disease (21.8 per 10,000 person-years) and valvular
heart disease (11.8 per 10,000 person-years; HR, 1.36,
95% CI =0.89-2.10) (data not shown). Patients were
most prevalent with ischemic heart disease accounted
for 10600 persons.
The pathophysiological mechanisms underlying this
reciprocal relationship between the heart and kidneys
are still enigmatic. In general, the pathophysiologies of
impaired renal function in cardiovascular disease are
multifactorial and are associated with decreased renal
perfusion, atherosclerosis and inflammation, endothelial
dysfunction, and neurohormonal activation [13-15]. Our
results suggest the importance of atherosclerotic risk
factors for developing CKD and this is consistent. More-
over, additional analyses that we made provide us more
information. Hypertensive heart disease, ischemic heart
disease, and chronic heart failure, but not rheumatic or
valvular heart disease, are the significant factors for
developing CKD in patients with heart disease. These
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factors, related heart disease, and chronic heart failure as
their terminal stage, for developing CKD. Growing evi-
dence suggests that atherosclerosis has direct effects on
the kidney, largely because of intrarenal microvascular
and glomerular disease that precedes the onset and
represents the silent phase of ischemic renal disease
[16-18]. Renal function abnormalities may exist at the
early stages of atherogenesis and in patients with evi-
dence of only extrarenal atherosclerosis and may pre-
cede the onset of overt ischemic nephropathy [18,19].
Indeed, nonobstructive atherosclerosis accelerates the
decrease of renal size and the increased of serum
creatinine level with age [18,20], implying that deteri-
oration of renal function is likely the result of direct
parenchyma compromise, likely provoked by athero-
genic factors. Reduced cardiac output leads to hypo-
perfusion of the kidney as the result of poor forward
flow is traditionally believed to be the main determin-
ant of worsening renal function in patients with heart
diseases [13].
The majority of patients with heart diseases may rep-
resent with increased central or peripheral congestion.
Venous congestion might be one of the important
factors for developing CKD. The presence of venous
congestion has been considered as a secondary
phenomenon due to the backward failure caused by
impaired cardiac output. However, no evidence of asso-
ciation between left ventricle ejection fraction and esti-
mated glomerular filtration rate can be consistently
demonstrated in recent publication [21]. Patients with
chronic heart failure and preserved left ventricle func-
tion appear to have similar estimated glomerular filtra-
tion rate than ones with impaired left ventricle function
(ejection fraction less than 45%). Thus, it is uncertain
whether the cardiac output still plays a crucial role in
influencing the renal dysfunction. The impact of venous
congestion, rather than cardiac output has risen in in-
fluencing CRS in recent years. It is recently considered
is primarily associated with developing renal impair-
ment in patients with advanced heart failure [22-24].
Transmission of venous congestion to the renal veins
further impairs the glomerular filtration rate [24-28].
Mullens et al. reported that in patients with advanced
decompensated heart failure, improvement of cardiac
index after therapy had a limited contribution to
worsening renal function [28]. The observations provide
important clinical information that preservation of car-
diac output without relieving venous congestion may
not necessarily avert the development of renal impair-
ment [27,28]. Increased central venous pressure and
venous congestion also causes an increase in renal inter-
stitial pressure, which might lead to a hypoxic status of
renal parenchyma, similar to the mechanism by whichhepatic congestion lead to hepatic dysfunction in heart
failure [29-32].
This study had the limitations inherent in its retro-
spective and observational design. The severity of heart
diseases and CKD was not quantified; thus, we were un-
able to measure whether the disease severity is asso-
ciated with a dose–response relationship. In addition,
the episodes of acute kidney injury during follow-up
period might affect the accuracy of accumulated inci-
dence in both study and control cohorts. Thus, our
results regarding the association of heart diseases and
CKD might be affected by referral bias. Moreover, physi-
cians other than nephrologists might diagnose CKD by
the definition of abnormal serum creatinine concentra-
tion. It is possible that some patients with earlier stages
(stage 1–2) of CKD were not identified. Although this
coding is somewhat less sensitive for identifying CKD in
its early stage, it is used as a measure of kidney function
by physicians other than nephrologists. Thus, the diag-
nostic values of patients with early stage CKD have not
yet been fully evaluated. Further studies addressing this
issue are warranted. Finally, we have not yet studied the
long-term effect of time-averaged risk factors. Thus, it
can not allow us to account the risk of CKD for changes
in risk factors over time.
Conclusions
Our data show that heart disease is tightly associated
with increasing risk of subsequent development of CKD.
It is mandatory to design a randomized controlled trial
aimed at identifying pathophysiologically sound inter-
ventions targeting the relationship that we identify.
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